RT Journal Article
SR Electronic
T1 Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 880
OP 884
DO 10.2967/jnumed.122.264533
VO 64
IS 6
A1 Gococo-Benore, Denise A.
A1 Kuhlman, Justin
A1 Parent, Ephraim E.
A1 Sharma, Akash
A1 Accurso, Joseph
A1 Yang, Ming
A1 Kendi, Ayse Tuba
A1 Johnson, Geoff
A1 Sonbol, Mohamad Bassam
A1 Hobday, Timothy
A1 Halfdanarson, Thorvardur R.
A1 Starr, Jason
YR 2023
UL http://jnm.snmjournals.org/content/64/6/880.abstract
AB The aim of the current study was to describe the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) with a very high liver tumor burden, defined as tumor involving more than 75% of the liver. Methods: We conducted a retrospective analysis of 371 patients who received at least 1 cycle of 177Lu-DOTATATE at Mayo Clinic for advanced gastroenteropancreatic neuroendocrine tumors. We identified 15 total patients with more than 75% liver involvement on 68Ga-DOTATATE PET/CT and with either a contrast-enhanced abdominal MRI or dual-phase abdominal CT examination. Results: Of the 15 patients with more than 75% liver involvement, 1 experienced hepatotoxicity (i.e., worsening liver enzymes or bilirubin) as defined by the Common Terminology Criteria for Adverse Events, version 5.0. No patients had grade 3–5 hepatotoxicity (i.e., clinical signs of liver failure). Conclusion: When considering the risk of liver injury from PRRT due to burden of disease, our data suggest that PRRT may be a safe option in patients with more than 75% liver involvement. Future efforts should be made to determine the safety profile of PRRT in patients with varying degrees of liver involvement.